Objective?To study the clinical effect of intravenous thrombolysis and bridging TREVO stent for thrombus removal in patients with carotid artery T-occlusion cerebral infarction. Methods?According to the random number table, 50 patients with carotid artery T-occlusion cerebral infarction admitted to Huangdao District People's Hospital of Qingdao from January 2019 to December 2020 were divided into the control group (25 cases) and the observation group (25 cases). Patients in the control group were treated with conventional intravenous thrombolysis, and patientsin the observation group were treated with intravenous thrombolysis bridging the TREVO stent. The recanalization rates of the two groups of patients after treatment were compared , the National Institutes of Health Stroke Scale (NIHSS) scores before and 24 h after treatment were compared , the modified Rankin amount Table (mRS) score before and 90 days after treatment were compared, the levels of soluble intercellular adhesion molecule-1 (sICAM-1), high-sensitivity C reactive protein (hs-CRP) and tumor necrosis factor-α (TNF-α) 24 h after treatment were compared. Results?The recanalization rate of patients in the observation group was 64.00%, which was higher than 36.00% in the control group; the NIHSS score 24 h after treatment, mRS score 90 d after treatment and serum sICAM-1, hs-CRP and TNF-α levels 24 h after treatment in the two groups were lower than those before treatment, and the observation group were lower than the control group (all P<0.05). Conclusion?Intravenous thrombolysis bridging the TREVO stent for thrombus removal in patients with carotid artery T-occlusion cerebral infarction can effectively improve the patient's vascular recanalization rate, reduce the patient's inflammatory response, improve nerve function, and improve the treatment effect.